Printer Friendly

PARKINSON'S DISEASE: GAINING SYMPTOMATIC CONTROL WHO IS RESPONSIBLE?

 PARKINSON'S DISEASE: GAINING SYMPTOMATIC CONTROL
 WHO IS RESPONSIBLE?
 A National Editorial Teleconference
 Sponsored by The Du Pont Merck Pharmaceutical Company
 WHAT: -- Leading neurologists highlight new data from a special
 issue of Neurology, official journal of the American
 Academy of Neurology
 -- Facts about benefits and challenges of conversion from
 standard Carbidopa-Levodopa therapy to sustained release
 treatment
 -- Patients discuss how new therapy enhances their lives
 WHY: -- Role of Neurologists: Pass on experience with new advanced
 therapy to primary care physicians
 -- Role of Family Physicians: Provide long-term care with
 most recent treatment
 -- Benefit: Many Parkinson's patients will gain more freedom
 from symptoms and require less frequent dosing with the
 first sustained release treatment for signs and symptoms of
 Parkinson's disease
 WHO: Leading Movement Disorder Specialists And Patients:
 -- William Koller, M.D., Ph.D.
 Professor and Chairman of Neurology
 Kansas University Medical Center
 -- Margery Mark, M.D.
 Assistant Professor of Neurology
 UMDNJ-Robert Wood Johnson Medical School
 -- Robert Glaser
 Parkinson's disease patient
 WHEN: 10 a.m., Wednesday, April 22
 WHERE: From your office desk via ATT teleconference hook-up
 CONTACT: Patty Bifulco, 212-468-3259, to arrange your telephone link-up.
 -0- 4/20/92


CO: ST: IN: MTC SU:

SM-LR -- NY094 -- 0302 04/20/92 18:49 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 20, 1992
Words:200
Previous Article:EPE ANNOUNCES 1991 FINANCIAL RESULTS
Next Article:UNION CARBIDE REPORTS FIRST QUARTER RESULTS


Related Articles
H. Lundbeck A/S and Centaur Pharmaceuticals, Inc. Join to Develop Pharmaceuticals for Parkinson's Disease
New Parkinson's Disease Drug Requip(TM) Now Available From SmithKline Beecham
Exercise, dairy intake tied to Parkinson's in men.
NIH Begins Phase II Clinical Testing of Guilford Pharmaceuticals' GPI 1485 for Parkinson's Disease.
Guilford Pharmaceuticals Initiates Phase II Trial of GPI 1485 for the Treatment of Parkinson's Disease.
Docs' Parkinson's risk.
FDA GRANTS ORPHAN DRUG DESIGNATION FOR DROXIDOPA.
FDA Approves SCHWARZ PHARMA's Neupro(R) (Rotigotine Transdermal System) for the Treatment of Early-Stage Parkinson's Disease in USA.
SCHWARZ PHARMA and UCB, Inc. Announce U.S. Launch of Neupro(R) (Rotigotine Transdermal System) for the Treatment of Early-Stage Parkinson's Disease.
CoQ10.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters